Puma Biotechnology, Inc.

Quick facts

Phase 2 pipeline

• HKI-272 · Oncology
  HKI-272 is a small molecule inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Puma Biotechnology, Inc. portfolio CI brief
• Puma Biotechnology, Inc. pipeline updates RSS